The Venture Codex Logo

The Venture Codex

Overview

Developing glycan-targeted therapies for respiratory infections and cancer.

Total Raised

$23 M

Rounds

4

Links

Verticals

Biotechnology
Health Care
Wellness

Investment History

  1. Equity

    Jun 2023

    $10M

  2. Equity

    Jan 2022

    $5M

  3. Equity

    Jan 2021

    $3M

  4. Equity

    May 2020

    $5M

Team

Douglas Thomson

Chief Executive Officer

Garry Taylor

Director and Chairman of Scientific Advisory Board

Helen Connaris

Co-founder and Chief Scientific Officer

Mark Bamforth OBE

Non-Executive Director